This paper moves the cluster from “what causes immune confusion?” to “how can we correct it?”
Previous work suggested that accumulated cell-free DNA can worsen rheumatoid arthritis by triggering immune alarm pathways. This study asks a practical follow-up question: can the body’s DNA cleanup system be strengthened? The answer points to TREX1, an enzyme that helps degrade misplaced DNA fragments.
The researchers screened natural compounds and identified pterostilbene and bilobalide as TREX1 activators. These compounds increased TREX1 expression and activity, reduced cfDNA accumulation, and lowered activation of the cGAS–STING pathway. In arthritis models, they helped reduce inflammation and joint damage. Importantly, when TREX1 was
knocked out, the protective effects were weakened. This confirms that TREX1 is not just associated with the effect; it is central to the mechanism.
The study is novel because it treats cfDNA clearance as a therapeutic target. Instead of only blocking inflammatory cytokines after RA develops, it aims to remove one of the upstream signals that may keep the immune system activated.
For the cluster topic of immune tolerance, this paper is especially valuable. It shows that restoring tolerance may not always require strong immune suppression. It may also involve helping the body clear its own misplaced DNA so the immune system no longer mistakes “self” for danger.
This gives the cluster a strong translational message: immune tolerance engineering may be possible through natural-product-based activation of DNA clearance pathways.
References
Y. Wang et al., “TREX1 activators: A novel therapeutic strategy for rheumatoid arthritis management via cfDNA clearance,” Pharmacological Research, vol. 218, article 107817, 2025. Doi: 10.1016/j.phrs.2025.107817
